Pilcer Gabrielle, Vanderbist Francis, Amighi Karim
Laboratory of Pharmaceutics and Biopharmaceutics, Université Libre de Bruxelles, Belgium.
Int J Pharm. 2009 Jan 5;365(1-2):162-9. doi: 10.1016/j.ijpharm.2008.08.014. Epub 2008 Aug 22.
Using high-pressure homogenization and spray-drying techniques, novel formulations were developed for manufacturing dry powder for inhalation, composed of a mixture of micro- and nanoparticles in order to enhance lung deposition. Particle size analysis was performed by laser diffraction. Spray-drying was applied in order to retrieve nanoparticles in dried-powder state from tobramycin nanosuspensions. The aerolization properties of the different formulations were evaluated by a multi-stage liquid impinger. Suspensions of nanoparticles of tobramycin containing Na glycocholate at 2% (w/w) relative to tobramycin content and presenting a mean particle size about 200 nm were produced. The results from the spray-dried powders showed that the presence of nanoparticles in the formulations improved particle dispersion properties during inhalation. The fine particle fraction (percentage of particles below 5 microm) increased from 36% for the raw micronized tobramycin material to about 61% for the most effective formulation. These new nanoparticle-containing tobramycin DPI formulations, based on the use of very low level of excipient and presenting high lung deposition properties, offer very important perspectives for improving the delivery of drugs to the pulmonary tract.
采用高压均质化和喷雾干燥技术,开发了用于制造吸入用干粉的新型制剂,其由微米和纳米颗粒的混合物组成,以提高肺部沉积率。通过激光衍射进行粒度分析。应用喷雾干燥从妥布霉素纳米悬浮液中获取干粉状态的纳米颗粒。通过多级液体撞击器评估不同制剂的雾化特性。制备了相对于妥布霉素含量含有2%(w/w)甘氨胆酸钠且平均粒径约为200nm的妥布霉素纳米颗粒悬浮液。喷雾干燥粉末的结果表明,制剂中纳米颗粒的存在改善了吸入过程中的颗粒分散特性。细颗粒分数(粒径低于5微米的颗粒百分比)从粗微粉化妥布霉素原料的36%增加到最有效制剂的约61%。这些基于使用极低水平赋形剂且具有高肺部沉积特性的新型含纳米颗粒妥布霉素干粉吸入剂制剂,为改善药物向呼吸道的递送提供了非常重要的前景。